Immune thrombocytopenia: a comprehensive review from pathophysiology to promising treatment modalities

References

• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–2393.
   PubMed Web of Science ®Google Scholar
• Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006;133:364–374.
   PubMed Web of Science ®Google Scholar
• Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009;145:235–244.
   PubMed Web of Science ®Google Scholar
• Imbach P, Kuhne T, Signer E. Historical aspects and present knowledge of idiopathic thrombocytopenic purpura. Br J Haematol. 2002;119:894–900.
   PubMed Web of Science ®Google Scholar
• Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus. 2011;9:262–273.
   PubMed Web of Science ®Google Scholar
• McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost. 2003;1:485–491.
   PubMed Web of Science ®Google Scholar
• Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol Suppl. 2008;80(s69):3–8.
   Google Scholar
• McMillan R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J Pediatr Hematol Oncol. 2003;25(Suppl 1):S57–61.
   PubMed Web of Science ®Google Scholar
• Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost. 2012;38:454–462.
   PubMed Web of Science ®Google Scholar
• Ma L, Simpson E, Li J, et al. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia. Blood. 2015;126:247–256.
   PubMed Web of Science ®Google Scholar
• Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123–1124.
   PubMed Web of Science ®Google Scholar
• Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood. 2010;115:1247–1253.
   PubMed Web of Science ®Google Scholar
• Cuker A, Cines DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2010;2010:377–384.
   PubMed Web of Science ®Google Scholar
• Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27:495–520.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457–3469.
   PubMed Web of Science ®Google Scholar
• Alexander WS, Roberts AW, Nicola NA, et al. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood. 1996;87:2162–2170.
   PubMed Web of Science ®Google Scholar
• Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 1998;95:379–391.
   PubMed Web of Science ®Google Scholar
• Sakakura M, Wada H, Tawara I, et al. Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 2007;120:187–193.
   PubMed Web of Science ®Google Scholar
• Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol. 2003;55:107–111.
   PubMed Web of Science ®Google Scholar
• Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001;84:227–229.
   PubMed Web of Science ®Google Scholar
• Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin North Am. 2010;24:249–273.
   PubMed Web of Science ®Google Scholar
• Breakey VR, Blanchette VS. Childhood immune thrombocytopenia: a changing therapeutic landscape. Semin Thromb Hemost. 2011;37:745–755.
   PubMed Web of Science ®Google Scholar
• Liebman HA. Viral-associated immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2008;2008(1):212–218.
   Google Scholar
• Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol. 2005;129:818–824.
   PubMed Web of Science ®Google Scholar
• Zhang W, Nardi MA, Borkowsky W, et al. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood. 2009;113:4086–4093.
   PubMed Web of Science ®Google Scholar
• Li Z, Nardi MA, Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood. 2005;106:572–576.
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113:6511–6521.
   PubMed Web of Science ®Google Scholar
• Hauswirth AW, Skrabs C, Schutzinger C, et al. Autoimmune thrombocytopenia in non-Hodgkin’s lymphomas. Haematologica. 2008;93:447–450.
   PubMed Web of Science ®Google Scholar
• Yoshimura C, Nomura S, Nagahama M, et al. Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura. Eur J Haematol. 2000;64:219–224.
   PubMed Web of Science ®Google Scholar
• Liebman HA. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders. Semin Hematol. 2009;46:S33–6.
   PubMed Web of Science ®Google Scholar
• Aster RH, Curtis BR, McFarland JG, et al. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost. 2009;7:911–918.
   PubMed Web of Science ®Google Scholar
• Chouhan JD, Herrington JD. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. Pharmacotherapy. 2010;30:666–683.
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–186.
   PubMed Web of Science ®Google Scholar
• Neylon AJ, Saunders PW, Howard MR, et al. Northern region haematology G. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966–974.
   PubMed Web of Science ®Google Scholar
• Psaila B, Petrovic A, Page LK, et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood. 2009;114:4777–4783.
   PubMed Web of Science ®Google Scholar
• Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes. 2007;5:11.
   PubMed Web of Science ®Google Scholar
• Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther. 2007;29:950–962.
   PubMed Web of Science ®Google Scholar
• Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98:1760–1764.
   PubMed Web of Science ®Google Scholar
• Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47:2170–2175.
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549–2554.
   PubMed Web of Science ®Google Scholar
• Neunert CE. Current management of immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2013;2013:276–282.
   PubMed Web of Science ®Google Scholar
• Borst F, Keuning JJ, van Hulsteijn H, et al. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004;83:764–768.
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109:1401–1407.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349:831–836.
   PubMed Web of Science ®Google Scholar
• Mashhadi MA, Kaykhaei MA, Sepehri Z, et al. Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia. Daru. 2012;20:7.
   PubMed Web of Science ®Google Scholar
• Stasi R, Brunetti M, Pagano A, et al. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis. 2000;26:582–586.
   PubMed Web of Science ®Google Scholar
• Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev. 2008;22:103–116.
   PubMed Web of Science ®Google Scholar
• Li Q, Yang M, Xia R, et al. Elevated expression of IL-12 and IL-23 in patients with primary immune thrombocytopenia. Platelets. 2015;26:453–458.
   PubMed Web of Science ®Google Scholar
• Tamminga R, Berchtold W, Bruin M, et al. Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS). Br J Haematol. 2009;146:180–184.
   PubMed Web of Science ®Google Scholar
• Liebman HA, Pullarkat V. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics. Hematology Am Soc Hematol Educ Program. 2011;2011:384–390.
   PubMed Web of Science ®Google Scholar
• Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol. 2013;38:275–284.
   PubMed Web of Science ®Google Scholar
• Chapman SA, Gilkerson KL, Davin TD, et al. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother. 2004;38:2059–2067.
   PubMed Web of Science ®Google Scholar
• Newman GC, Novoa MV, Fodero EM, et al. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol. 2001;112:1076–1078.
   PubMed Web of Science ®Google Scholar
• Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689–2700.
   PubMed Web of Science ®Google Scholar
• Meyer O, Kiesewetter H, Hermsen M, et al. Replacement of intravenous administration of anti-D by subcutaneous administration in patients with autoimmune thrombocytopenia. Pediatr Blood Cancer. 2006;47:721–722.
   PubMed Web of Science ®Google Scholar
• Robak T, Windyga J, Trelinski J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood. 2012;120:3670–3676.
   PubMed Web of Science ®Google Scholar
• Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25–33.
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhang L, Gao J, et al. Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One. 2012;7:e36698.
   PubMed Web of Science ®Google Scholar
• Patel VL, Mahevas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119:5989–5995.
   PubMed Web of Science ®Google Scholar
• Hasan A, Michel M, Patel V, et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol. 2009;84:661–665.
   PubMed Web of Science ®Google Scholar
• Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112:1147–1150.
   PubMed Web of Science ®Google Scholar
• Mahevas M, Patin P, Huetz F, et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest. 2013;123:432–442.
   PubMed Web of Science ®Google Scholar
• Hanbali A, Khaled Y. Incidence of hepatitis B reactivation following rituximab therapy. Am J Hematol. 2009;84:195.
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood. 2009;113:4834–4840.
   PubMed Web of Science ®Google Scholar
• Maloisel F, Andres E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004;116:590–594.
   PubMed Web of Science ®Google Scholar
• Ahn YS, Rocha R, Mylvaganam R, et al. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med. 1989;111:723–729.
   PubMed Web of Science ®Google Scholar
• Quiquandon I, Fenaux P, Caulier MT, et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990;74:223–228.
   PubMed Web of Science ®Google Scholar
• Taylor A, Neave L, Solanki S, et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. 2015;171:625–630.
   PubMed Web of Science ®Google Scholar
• Verlin M, Laros RK Jr., Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol. 1976;1:97–104.
   PubMed Web of Science ®Google Scholar
• Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85:351–358.
   PubMed Web of Science ®Google Scholar
• Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. J Thromb Haemost. 2013;11:1946–1953.
   PubMed Web of Science ®Google Scholar
• Huhn RD, Fogarty PF, Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood. 2003;101:71–77.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Rabusin M, Musso M, et al. Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. Br J Haematol. 2004;125:749–755.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. New thrombopoietic growth factors. Clin Lymphoma Myeloma. 2009;9(Suppl 3):S347–56.
   PubMedGoogle Scholar
• D’Arena G, Guariglia R, Mansueto G, et al. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. Blood. 2013;121:1240–1242.
   PubMed Web of Science ®Google Scholar
• Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115:3339–3347.
   PubMed Web of Science ®Google Scholar
• Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004;25:52–60.
   PubMed Web of Science ®Google Scholar
• Evangelista ML, Amadori S, Stasi R. Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use. Curr Drug Discov Technol. 2007;4:162–173.
   PubMedGoogle Scholar
• Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99:4–13.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672–1681.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118:28–36.
   PubMed Web of Science ®Google Scholar
• Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27:424–430.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–2247.
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs. 2008;68:901–912.
   PubMed Web of Science ®Google Scholar
• Yamane N, Tanaka Y, Ohyabu N, et al. Characterization of novel non-peptide thrombopoietin mimetics, their species specificity and the activation mechanism of the thrombopoietin receptor. Eur J Pharmacol. 2008;586:44–51.
   PubMed Web of Science ®Google Scholar
• Erhardt JA, Erickson-Miller CL, Aivado M, et al. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol. 2009;37:1030–1037.
   PubMed Web of Science ®Google Scholar
• Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739–4741.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs. 2009;69:567–576.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641–648.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Psaila B, Saleh MN, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura. Blood. 2008;112:3431.
   Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura. Blood. 2008;3432.
   Google Scholar
• BaB P, James B, Linden MD, et al. In vivo effects of Eltrombopag on human platelet function. Blood. 2007;110:1301.
   PubMed Web of Science ®Google Scholar
• Dj K, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161:411–423.
   PubMed Web of Science ®Google Scholar
• Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121:537–545.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Aledort L, Mathias SD, et al. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value Health. 2011;14:90–96.
   PubMed Web of Science ®Google Scholar
• Chihara K, Kimura Y, Honjo C, et al. Syk inhibitors. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36:197–202.
   PubMedGoogle Scholar
• Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113:3154–3160.
   PubMed Web of Science ®Google Scholar
• Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol. 2008;141:545–548.
   PubMed Web of Science ®Google Scholar
• Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther. 2015;32:875–887.
   PubMed Web of Science ®Google Scholar